Y-27632 Dihydrochloride: A Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective small-molecule inhibitor of Rho-associated kinases ROCK1 and ROCK2, with an IC₅₀ of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2, offering over 200-fold selectivity against other kinases (ApexBio). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression, making it a key tool in cytoskeletal, stem cell, and cancer research (Liu et al., 2021). The compound demonstrates robust solubility in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL), supporting various experimental workflows. In vitro and in vivo studies confirm its utility in suppressing tumor cell proliferation and invasion. Its specificity and reproducibility have led to widespread adoption in basic and translational research.

Biological Rationale

Rho-associated protein kinases, ROCK1 and ROCK2, are serine/threonine kinases that regulate cytoskeletal dynamics, cell motility, and proliferation. Aberrant activation of the Rho/ROCK pathway contributes to pathological processes, including cancer cell invasion, metastasis, and impaired cytokinesis (Liu et al., 2021). Pharmacological inhibition of ROCK kinases permits the dissection of these processes in model systems. Y-27632 dihydrochloride is an established chemical probe for studying the effects of ROCK inhibition in both normal and disease states. Its use has clarified the role of Rho/ROCK signaling in myosin light chain phosphorylation, stress fiber formation, and tumor cell invasiveness.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds competitively to the ATP-binding pocket within the catalytic domains of ROCK1 and ROCK2. This interaction inhibits kinase activity, with reported IC₅₀ values of 140 nM (ROCK1) and K_i of 300 nM (ROCK2) (ApexBio). The compound exhibits more than 200-fold selectivity for ROCK isoforms over related kinases, including PKC, MLCK, PAK, and cAMP-dependent protein kinase. Inhibition of ROCK impairs phosphorylation of downstream targets such as myosin light chain (MLC), leading to disassembly of actin stress fibers and decreased cellular contractility. This disruption modulates cell morphology, adhesion, and migration. Notably, Y-27632 does not inhibit upstream Rho GTPase activity or directly affect actin polymerization.

Evidence & Benchmarks

• Y-27632 dihydrochloride at 10 μM reversibly inhibits ROCK-dependent myosin light chain phosphorylation and suppresses breast cancer cell invasion (Liu et al., 2021).
• ROCK inhibition by Y-27632 leads to a concentration-dependent reduction in prostatic smooth muscle cell proliferation in vitro (ApexBio).
• In mouse tumor models, Y-27632 administration reduces tumor invasion, metastasis, and the formation of abnormal pathological structures (Liu et al., 2021).
• Stock solutions are stable for several months at ≤-20°C, with best practice being to avoid long-term storage of solutions to prevent degradation (ApexBio).
• Y-27632 enhances survival and attachment of dissociated stem cells, prolonging viability in culture (Egg White Lysozyme).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is utilized in diverse research contexts. Its primary applications include:

• Dissecting Rho/ROCK signaling pathways in cancer, stem cell, and neurobiological models.
• Enhancing stem cell viability post-dissociation and during transplantation workflows (Egg White Lysozyme).
• Inhibiting actomyosin contractility to study cytokinesis, migration, and tissue morphogenesis (Type I Hair Keratin Fragment).

This article updates and extends prior coverage by detailing quantitative selectivity, solubility, and direct mechanistic benchmarks, going beyond workflow tutorials in America Peptides.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; its effects are highly selective for ROCK1 and ROCK2, with minimal off-target activity at standard concentrations.
• Inhibition is reversible and does not produce permanent changes in cell phenotype after washout.
• Y-27632 does not inhibit upstream Rho GTPase activation or downstream effectors unrelated to ROCK, such as LIMK or cofilin, unless indirectly via cytoskeletal changes.
• The compound does not function as a direct apoptosis inducer; observed cell survival effects are due to cytoskeletal stabilization and anti-anoikis mechanisms.
• Solubility and stability are dependent on solvent and temperature; improper storage or repeated freeze-thaw cycles can lead to reduced potency.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. For experimental use, stock solutions can be prepared in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL). Solubility can be increased by gentle warming (37°C) or ultrasonic treatment. For cell culture, typical working concentrations range from 1–10 μM. Stock solutions are stable for several months at ≤-20°C, but repeated freeze-thaw cycles are discouraged. In vitro assays should monitor for cytoskeletal changes within 1–4 hours after compound addition. For in vivo use, dosing regimens must be optimized according to species, tumor model, and desired pharmacodynamic endpoints (ApexBio).

Compared to other ROCK inhibitors, Y-27632 offers superior selectivity, well-defined dose-response relationships, and validated workflows for stem cell and cancer applications (Lopermide).

Conclusion & Outlook

Y-27632 dihydrochloride (SKU: A3008) is a cornerstone reagent for dissecting the Rho/ROCK axis in cell biology, cancer, and regenerative medicine. Its high selectivity, robust solubility, and reproducible effects on cytoskeletal architecture and tumor cell behavior make it an essential tool for mechanistic and translational studies. For current protocols, refer to the product page. Further research is anticipated to extend its applications in organoid technology, aging, and complex tissue engineering, as outlined in recent reviews (BMS345541 Hydrochloride).